302 related articles for article (PubMed ID: 23574746)
1. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
2. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
3. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
4. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
5. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
6. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
7. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
Shin SB; Woo SU; Chin YW; Jang YJ; Yim H
J Cell Physiol; 2017 Oct; 232(10):2818-2828. PubMed ID: 27861885
[TBL] [Abstract][Full Text] [Related]
9. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.
Smith L; Farzan R; Ali S; Buluwela L; Saurin AT; Meek DW
Sci Rep; 2017 Nov; 7(1):16115. PubMed ID: 29170437
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Choi M; Kim W; Cheon MG; Lee CW; Kim JE
Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
13. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M; Bakar-Ates F
Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
[TBL] [Abstract][Full Text] [Related]
14. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Stehle A; Hugle M; Fulda S
Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
[TBL] [Abstract][Full Text] [Related]
15. PLK1 targets NOTCH1 during DNA damage and mitotic progression.
De Blasio C; Zonfrilli A; Franchitto M; Mariano G; Cialfi S; Verma N; Checquolo S; Bellavia D; Palermo R; Benelli D; Screpanti I; Talora C
J Biol Chem; 2019 Nov; 294(47):17941-17950. PubMed ID: 31597699
[TBL] [Abstract][Full Text] [Related]
16. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
17. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications.
Shakeel I; Basheer N; Hasan GM; Afzal M; Hassan MI
J Drug Target; 2021 Feb; 29(2):168-184. PubMed ID: 32886539
[TBL] [Abstract][Full Text] [Related]
18. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
[TBL] [Abstract][Full Text] [Related]
19. Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines.
Driscoll DL; Chakravarty A; Bowman D; Shinde V; Lasky K; Shi J; Vos T; Stringer B; Amidon B; D'Amore N; Hyer ML
PLoS One; 2014; 9(11):e111060. PubMed ID: 25365521
[TBL] [Abstract][Full Text] [Related]
20. Non-mitotic functions of polo-like kinases in cancer cells.
Raab CA; Raab M; Becker S; Strebhardt K
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
